The Peptide Field
Menu

6 FDA label and trial tables · Checked

Urinary tract infections vs placebo, out of 100 people

Saxenda label

Placebo3.1%
On Saxenda4.3%

In the Saxenda label, 4.3% on Saxenda had urinary tract infections. On placebo, 3.1% did.

See all 6 tables

Every table that lists urinary tract infections

Each dot is 1 in 100 people.

Reported it Rest of a dose range Did not report it

Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.

FDA-approved medicines

SaxendaFDA-approved product

Saxenda trials in adults, less common problems

Row in the source: Urinary tract infections

Placebo3.1%
On Saxenda4.3%
Who was studied
Adults with obesity or overweight in 5 trials. 3,384 got Saxenda and 1,941 got placebo. 15% had type 2 diabetes. Everyone also got advice on diet and exercise.
How long
32 to 56 weeks, some up to about 3 years
Source
Saxenda prescribing information on DailyMed . FDA label revised February 2026.

WegovyFDA-approved product

Wegovy trial in teens with obesity

Row in the source: Urinary tract infection

Placebo2%
On Wegovy4%
Who was studied
Children aged 12 and older with obesity. 133 got Wegovy and 67 got placebo.
How long
68 weeks
Source
Wegovy prescribing information on DailyMed . FDA label revised June 2026.

Medicines that are not FDA-approved

CagrilintideNo FDA-approved product

Phase 2 weight trial (NCT03856047), less common problems

Row in the source: Urinary tract infections

Placebo2.0%
On cagrilintide (by dose)1.0% to 7.0%
Who was studied
706 adults without diabetes who had obesity, or overweight with high blood pressure or unhealthy blood-fat levels. 506 got cagrilintide and 101 got placebo. A liraglutide group of 99 is not shown.
How long
26 weeks of treatment, side effects counted to week 32
Source
ClinicalTrials.gov posted results . Trial registry results posted July 18, 2023.

RetatrutideNo FDA-approved product

TRIUMPH-1

Row in the source: Urinary tract infections

Placebo5.3%
On retatrutide (by dose)7.5% to 8.8%
Who was studied
Adults without diabetes who had obesity, or overweight and at least one health problem linked to weight.
How long
80 weeks
Source
Lilly early results . Company trial results posted May 21, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

TRIUMPH-2

Row in the source: Urinary tract infections

Placebo6.6%
On retatrutide (by dose)3.8% to 8.0%
Who was studied
Adults with type 2 diabetes and obesity or overweight.
How long
80 weeks
Source
Lilly early results . Company trial results posted July 23, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

TRIUMPH-3

Row in the source: Urinary tract infections

Placebo5.3%
On retatrutide (by dose)6.1% to 7.0%
Who was studied
Adults with severe obesity and heart or blood vessel disease, with or without type 2 diabetes.
How long
80 weeks
Source
Lilly early results . Company trial results posted July 23, 2026. Company trial results were not yet checked by outside experts when we read them.

How long were people watched?

Each bar is one set of trials. The dots on this page come only from the time inside each bar.

Stated length Range in the source Some people only

  1. Saxenda, adults32 to 56 weeks, some up to about 3 years

  2. Wegovy, teens68 weeks

  3. Cagrilintide, phase 226 weeks of treatment, side effects counted to week 32

  4. Retatrutide, TRIUMPH-180 weeks

  5. Retatrutide, TRIUMPH-280 weeks

  6. Retatrutide, TRIUMPH-380 weeks

Trials can miss rare harms and harms that take years to appear.

Other side effects

Pick a medicine and side effect

Where the numbers come from

Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.

We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.

The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.

Report a side effect

You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.

Did this page answer your question?